跳到正文
原文
MedPage Today·· 10 天前精选AI 评分75

双靶点抑制剂在二期试验中对皮肤嗜酸性粒细胞增多性肉芽肿病疗效显著

Cutaneous Sarcoidosis Could Soon Get an Effective Therapy

AI 导读

双靶点抑制剂brepocitinib在二期试验中对皮肤嗜酸性粒细胞增多性肉芽肿病疗效显著,患者CSAMI-A评分显著下降,无严重不良反应。研究者认为该药可能成为一线治疗选择,但需等待更大规模三期试验结果。

推荐理由

双靶点抑制剂在小样本二期试验中对皮肤嗜酸性粒细胞增多性肉芽肿病疗效显著,为该病治疗带来新希望。

正文 · 原文

— Drug already approved for dermatomyositis passes phase II test

by John Gever, Contributing Writer, MedPage Today

November 10, 2026 • 4 min read

ORLANDO -- Patients with cutaneous sarcoidosis -- a condition with no very effective therapy -- saw dramatic improvement with the dual-acting TYK2/JAK1 inhibitor brepocitinib (Lisraya) in a small phase II trial.

Patients treated with either of two doses of brepocitinib achieved 22-point reductions in Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) scores after 16 weeks, well above the 5-point threshold for clinical relevance, compared with no decrease at all with placebo, reported Misha Rosenbach, MD, of the University of Pennsylvania in Philadelphia, and colleagues.

The drug also showed strong efficacy for secondary outcomes, the group found, and no serious adverse effects were recorded. The study was published in JAMA Dermatology and was also presented here at the American College of Rheumatology annual meeting.

Cutaneous sarcoidosis might be the biggest treatment challenge in all of dermatology. Corticosteroids have long been the mainstay of therapy, but are only sporadically effective and, among patients who do respond, relapses are common. Second-line treatments such as hydroxychloroquine, methotrexate, or tetracyclines don't do much better. Tumor necrosis factor (TNF) inhibitors were recommended as third-line therapy in a 2021 treatment guideline, but on very poor evidence. A French case series published in 2017 suggested TNF inhibitors could be used effectively, but the authors noted that adverse effects and discontinuations were common, and one-third of patients relapsed while on therapy.

With this dismal treatment landscape in mind, clinicians have turned to Janus kinase (JAK) inhibitors as a possible alternative. Drugs such as tofacitinib (Xeljanz) and upadacitinib (Rinvoq) have been tried with some success, but only in single case reports and small series. Good results were also reported last year with the currently approved TYK2 inhibitor deucravacitinib (Sotyktu) in one patient.

All that bodes well for brepocitinib, which the FDA approved in August for dermatomyositis, and the phase II data in sarcoidosis appear to bear out the promise. Rosenbach and colleagues enrolled 31 patients, randomizing them in a 3:2:2 ratio to 45 or 15 mg/day of brepocitinib or placebo; they could stay on their conventional non-targeted therapies, but oral steroids were withdrawn over the first 8 weeks and topical steroids were stopped at randomization.

Patients were generally in their 40s and 50s. Mean disease duration varied in the three arms: about 10 years for the placebo and high-dose brepocitinib groups, and 4 years in the low-dose group. CSAMI-A scores averaged about 34 at baseline. Roughly 40% of participants had lupus pernio, the lumpy discolored facial and cranial lesions that may be the worst symptom of cutaneous sarcoidosis. Pulmonary sarcoidosis was also common in the sample.

Change from baseline in CSAMI-A score was the primary outcome measure. While no difference between the two brepocitinib doses was seen for this endpoint, "high-bar" outcomes showed some gaps. All patients in the high-dose group saw at least 10-point reductions in CSAMI-A scores, compared with 73% on the low dose (and 14% in the placebo group). Similarly, "functional remission," defined as a score below 5, was achieved by 62% with 45 mg versus 46% on 15 mg, and none receiving placebo.

Perhaps most encouragingly, all five patients in the 45-mg group with lupus pernio achieved 10-point reductions in CSAMI-A scores. Patients on the active drug also had substantial improvement in skin-related quality of life, whereas the placebo group actually had deterioration. (The near-total lack of improvement with placebo for any efficacy outcome testifies to just how difficult cutaneous sarcoidosis is to treat.)

With regard to safety, one patient in each arm quit therapy because of adverse events. But none were rated as serious. One patient on 45 mg showed a creatinine kinase elevation, and one developed anemia. Otherwise, no "special interest" events were seen; these included cardiovascular events, viral reactivation, transaminase elevations, venous thromboembolism, and malignancies.

Following his conference presentation, Rosenbach was asked where brepocitinib might fit in the treatment algorithm for cutaneous sarcoidosis. He cautioned that it was still early to speculate on that, since a larger phase III trial is only just getting underway. But if those data are like those he reported, "I imagine many patients would get it as first line," he said.

He was also asked about effects on pulmonary and joint manifestations, which are common in cutaneous sarcoidosis. He said the studies thus far have really focused on skin, and he couldn't say much about other symptoms. He added, though, that these would almost certainly be examined in the phase III trial.

Brepocitinib's developer, Priovant Therapeutics, expects primary results from the phase III study at the end of 2028. Rosenbach said the 45-mg dose will be the one tested for potential approval. Additional trials are underway in uveitis and lichen planopilaris; there's no indication, however, that Priovant plans to challenge deucravacitinib, which is approved for plaque psoriasis and psoriatic arthritis.

来源:MedPage Today · medpagetoday.com